All In Biotech

Drug Trial Radar · NCT06349473

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)

A Phase 1 Single and Multiple Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Healthy Participants (Part A) and the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SR604 in Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency (Part B)

Last checked: Nov 19, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

31

Planned (sponsor's estimate)

Start

May 10, 2024

Primary completion

Sep 28, 2026

Study completion Sep 28, 2026

Sponsor

Lead sponsor
Equilibra Bioscience LLCIndustry
Sponsor type
Industry
First posted
Apr 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) of SR604 in healthy participants (Part A) and to evaluate the safety, tolerability, PK, PD, and efficacy of SR604 in participants with Hemophilia A or Hemophilia B, or Factor VII (FVII) deficiency, with or without inhibitors (Part B).

Conditions

  • Healthy Participants
  • Hemophilia A
  • Hemophilia B
  • Factor VII Deficiency

Interventions

  • SR604Drug

    SR604 will be administered as SC injection.

  • PlaceboDrug

    Placebo will be administered as single SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts A and B: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Part A: From Baseline (Day 1) up to Day 57; Part B: From Baseline (Day 1) up to 3 months
  2. Parts A and B: Number of Participants with Clinical Abnormal Changes in Coagulations MarkersTime frame: Part A: From Baseline (Day 1) till Day 57; Part B: From Baseline (Day 1) till Day 90

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • California Clinical Trials Medical Group (CCTMG)

    Glendale, California · Completed

  • Children's Hospital Los Angeles

    Los Angeles, California · Recruiting

  • Rush University Medical Center

    Chicago, Illinois · Recruiting

  • LA Center for Bleeding and Clotting Disorders - Metairie

    Metairie, Louisiana · Recruiting

  • University of Michigan Hospitals - Michigan Medicine

    Ann Arbor, Michigan · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Brody School of Medicine at East Carolina University

    Greenville, North Carolina · Not yet recruiting

  • Penn State Milton S Hershey Medical Center Pediatrics

    Hershey, Pennsylvania · Recruiting

  • Perelman Center for Advanced Medicine (PCAM)- Penn Blood Disorders Program

    Philadelphia, Pennsylvania · Recruiting

  • McMaster University Medical Centre, Hamilton Health Sciences

    Hamilton, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.